Dianthus Therapeutics Inc expected to post a loss of 85 cents a share - Earnings Preview

Dianthus Therapeutics

05/05/2025 12:46

Dianthus Therapeutics Inc DNTH.OQ DNTH.O is expected to show a fall in quarterly revenue when it reports  results on May 7 (estimated) for the period ending March 31 2025

The New York City-based  company is expected to report a 8.0% decrease in revenue to $804.3 thousand from $874 thousand a year ago, according to the mean estimate from 10 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Dianthus Therapeutics Inc is for a loss of 85 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Dianthus Therapeutics Inc is $52.00​, above​ its last closing price of $21.70. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.88
-0.85
-0.81
Beat
4.8
Sep. 30 2024
-0.58
-0.59
-0.74
Missed
-24.5
Jun. 30 2024
-0.57
-0.55
-0.51
Beat
6.5​
Mar. 31 2024
-0.44
-0.44
-0.54
Missed
-23.3
​​Dec. 31 2023
-1.18
-1.01
-0.71
Beat
29.7
Sep. 30 2023
-0.56
-0.56
-3.78
Missed
-575​
Jun. 30 2023
-3.04
-3.04
-0.80
Beat
73.7
Mar. 31 2023
-6.56
-6.56
-7.68
Missed
-17.1

This summary was machine generated May 5 at 11:46 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)